Mimicking nature’s antibodies


Monoclonal antibodies (mAbs) synthesised in the laboratory aim to mimic natural antibodies which are produced by the body to selectively 和 specifically target pathogenic proteins or antigens in response to infection 和 neutralise them. When used as a therapeutic, mAbs employ the same approach to seek out 和 neutralise the target of interest.

Over the past three decades, mAbs have revolutionised the treatment of infectious diseases, cancer 和 chronic immunological diseases. Building on our long-st和ing heritage in this field from 剑桥 Antibody Technology (CAT) 和 MedImmune, we harness our extensive antibody discovery 和 protein engineering platform to design mAbs for therapeutic applications. 例如, we are able to optimise mAbs using our proprietary extended half-life technology which can extend the length of protection of the mAbs in the body. We are also using these platforms to design 马伯片段双特异性马伯, which can potentially offer wider therapeutic benefits unique to these modalities.

In addition to uncovering innovative ways to incorporate antibodies in cutting-edge therapies 和 diagnostics across oncology, we are developing novel mAbs that can target different drivers of inflammation in a number of respiratory 和 immunological conditions such as asthma 和 chronic obstructive pulmonary disease (COPD), as well as against infectious diseases such as respiratory syncytial virus (RSV) 和 COVID-19.1,2


参考文献

1. Griffin MP, Yuan Y, Takas T, et al. Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants [published correction appears in [英]医学. 2020年7月29日;:]. [英]医学. 2020;383(5):415-425. doi: 10.1056/NEJMoa1913556.

2. Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing 和 protective human antibodies against SARS-CoV-2 [published online ahead of print, 2020年7月15日]. 自然. 2020;10.1038/s41586-020-2548-6. doi: 10.1038/s41586-020-2548-6.



加入澳门葡京赌博游戏

If you believe in the power of what science can do, join us in our endeavour to push the boundaries of science to deliver life-changing medicines.


Collaborate with us

We know that however innovative our science, however effective our medicines 和 delivery, to achieve all we want to achieve, we cannot do it alone.


Veeva ID: Z4-46773
Date of preparation: August 2022